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Summary
Background Tolerability of treatments for multiple myeloma can depend on the characteristics of the patient being 
treated. We aimed to develop and validate a risk profile, using routinely collected data, that could predict overall 
survival in patients with multiple myeloma who were ineligible for stem-cell transplantation.
Methods We used patient data from two randomised controlled trials done in patients with newly diagnosed multiple 
myeloma who were ineligible for stem-cell transplantation (the NCRI Myeloma XI study [NCRI-XI, n=1852] and the 
MRC Myeloma IX study [MRC-IX, n=520]), to develop the UK Myeloma Research Alliance Risk Profile (MRP) for 
overall survival. We used multivariable Cox regression with a least absolute shrinkage and selection operator penalty 
term. Multiple imputation by chained equations was used to account for missing data in the development and internal 
validation of the model. The MRP was internally validated in NCRI-XI and externally validated in MRC-IX. The 
D-statistic was estimated in the developed model and used to internally and externally validate the model according to 
prespecified criteria.
Findings The MRP included WHO performance status, International Staging System, age, and C-reactive protein 
concentration as prognostic variables. The MRP was prognostic of overall survival and was successfully internally 
validated in NCRI-XI and externally validated in MRC-IX (D-statistic NCRI-XI: 0·840 [95% CI 0·718–0·963] and 
MRC-IX: 0·654 [0·497–0·811]). The MRP groups defining low-risk, medium-risk, and high-risk patients were 
associated with progression-free survival and early mortality. A decrease in the percentage of protocol dose delivered 
and quality of life at baseline were associated with increased risk. The MRP groups remained prognostic in patients 
exposed to different therapeutic combinations and in patients with genetic high-risk disease defined according to 
both the UK and International Myeloma Working Group definitions.
Interpretation We have developed and externally validated a risk profile for overall survival containing widely available 
clinical parameters. This risk profile could aid decision making in patients with multiple myeloma ineligible for 
stem-cell transplantation, but further external validation is required.
Funding Medical Research Council, Novartis, Schering Health Care, Chugai, Pharmion, Celgene, Ortho Biotech, 
Cancer Research UK, Celgene, Merck Sharp & Dohme, and Amgen.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Multiple myeloma is molecularly heterogeneous, but the 
patients it affects are also heterogeneous. This hetero­
geneity becomes more notable in older, less fit patients 
in whom factors affecting their ability to withstand 
treatment might be more important than disease biology.1 
Myeloma is predominantly a disease associated with 
advanced age, with 45% of patients aged 75 years and 
older at diagnosis;2 these patients represent a substantial 
proportion of newly diagnosed patients requiring 
treatment, yet they are historically underrepresented in 
clinical trials.3 Ageing is the leading risk factor for most 
chronic conditions that affect survival, independence, 
and wellbeing. These disorders, including atherosclerosis, 
cancer, dementias, and metabolic syndromes, are 
becoming progressively more prevalent as the elderly 
population increases. Age­related frailty syndrome is an 
entity defined as a heightened vulnerability to stresses 
(eg, surgery, infection, or trauma) coupled with 
sarcopenia and cachexia. Inflammation is the key 
physiological correlate of this syndrome, which 
predisposes to chronic disease, loss of independence, 
and mortality, and greatly increases health­care costs.4
Tolerability of anticancer therapy does not deteriorate 
linearly with age, so defining which patients are most at 
risk of outcome, measured with patient­reported or 
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biophysical measurements, might enable better treatment 
stratification. The Katz Activity of Daily Living (ADL),5 
Lawton’s Instrumental Activity of Daily Living (IADL),6 
and the Charlson Comorbidity Index (CCI)7 have been 
combined with age to derive the International Myeloma 
Working Group (IMWG) Frailty Score,8 which can predict 
patient outcome and has been prospectively externally 
validated in a single­centre study.9 Investigative work by 
several researchers has produced several variants of the 
frailty score devised by the IMWG.8,10 However, the main 
limitations of these scoring systems are their inherent 
subjectivity and the time that they require to administer in 
the clinic. A simpler, objective tool is needed that defines 
subpopulations at risk of early mortality and poor treatment 
tolerability, both of which restrict durability of response 
and ultimately overall survival. One potential approach is 
to use host response biomarkers based on biochemical and 
haematological indices. Several such markers have been 
found to be associated with adverse outcomes, including 
inflammatory markers such as C­reactive protein (CRP),11 
renal dysfunction,12 and the ratio of lymphocytes to total 
white blood cells.13 The use of laboratory markers to 
measure a patient’s susceptibility to early mortality and 
treatment­related toxicity is objective and easy to 
implement with routinely measured parameters.
The primary aim of this analysis was to develop and 
validate a scoring system based on readily available and 
routinely collected clinical and laboratory data that could 
predict overall survival in transplant­ineligible patients. 
Exploratory objectives were to analyse the groups derived 
from the scoring system for association with progression­
free survival, early mortality, dose delivery, baseline 
patient­reported health­related quality of life, and the 
independence of outcome prediction within various 
subgroups of patients.
Methods
Study design and participants
All newly diagnosed patients recruited to the non­
intensive treatment pathway of the National Cancer 
Research Institute Myeloma XI study (NCRI­XI, 
ISRCTN49407852) were considered for inclusion in the 
training dataset and all those included in the training 
dataset were also included in the internal validation 
dataset. Similarly, all newly diagnosed patients recruited 
to the Medical Research Council Myeloma IX study 
(MRC­IX, ISRCTN68454111) were considered for 
inclusion in the test dataset. 
The NCRI­XI trial was a phase 3, open­label, parallel­
group, multi­arm, adaptive design trial with three 
Research in context
Evidence before this study
Multiple myeloma is a disease that predominantly occurs in 
older patients in whom age-related physiological 
decompensation can lead to clinical frailty syndrome, which 
predisposes individuals to chronic disease, loss of independence, 
and mortality. Tolerability of anticancer therapy can impede 
treatment, affecting disease response and survival. Host-related 
factors have as much importance as tumour genomics in 
predicting outcomes in multiple myeloma. The International 
Myeloma Working Group (IMWG) published a Frailty Score in 
2015 that predicts patient outcome, but this score has 
limitations in terms of the feasibility of implementing it in 
clinical practice and its objectivity. Before doing our study, we 
reviewed all publications citing the IMWG Frailty Score 
publication using a Web of Science Core Collection Cited 
Reference Search. This search was updated on Aug 1, 2018, and 
covered the period from the online publication of the IMWG 
Frailty Score on Jan 27, 2015. All abstracts were screened by 
DAC and K-LR and reviewed in detail by DAC.
Added value of this study
We have developed a risk profile which is quick to implement 
and objective for use in patients with multiple myeloma who 
are ineligible for stem-cell transplantation. The risk profile 
uses commonly collected clinical data and is simpler to use 
than the IMWG Frailty Score. We have shown that the risk 
profile is associated with clinical outcomes (overall survival, 
progression-free survival, and early mortality) as well as 
intended delivery of therapy (proportion of protocol dose 
delivered). The risk profile retained prognostic potential in 
patients treated with therapeutic agents with differing 
mechanisms of action—alkylating agent regimens, 
immunomodulatory triplets, and proteasome 
inhibitors—suggesting that its prognostic capabilities are 
treatment agnostic. The risk profile also remained prognostic 
across different cytogenetic risk groups, emphasising that in 
older patients, outcome is driven by both tumour and host 
biology.
Implications of all the available evidence
The ability of clinical scoring systems, such as that proposed here, 
to predict whether a patient is likely to stop treatment early 
because of treatment intolerability, could enable pre-emptive, 
upfront dose adjustments in patients with multiple myeloma, 
preventing toxicity and potentially enabling patients to stay on 
therapy for longer. This risk profile we developed could influence 
survival, but this hypothesis needs to be tested. None of the risk 
scoring systems previously developed in myeloma are dynamic, 
making them unable to accommodate changes in disease-related 
frailty that might be minimised by effective anti-myeloma 
therapy. There is therefore scope to improve clinical risk scores by 
the addition of a suitable frailty biomarker, which is currently still 
in developmental stages. The use of risk profiles to direct therapy 
is an exciting possibility that will be explored further in 
collaborative clinical trials (eg, the UK-MRA Myeloma XIV 
[FiTNEss] study).
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random isation stages done at 110 National Health Service 
(NHS) hospitals in England, Scotland, and Wales. The 
MRC­IX trial was a phase 3, open­label, two­by­two 
factorial design trial with two randomisation stages done 
at 120 NHS hospitals in England, Northern Ireland, 
Scotland, and Wales. Inclusion and exclusion criteria 
were broadly similar in both studies. Eligible patients 
were aged 18 years and older, with symptomatic multiple 
myeloma based on bone marrow clonal plasma cells and 
related organ or tissue impairment. Exclusion criteria 
included previous or concurrent malignancies, including 
myelo dysplastic syndromes, previous treatment for 
myeloma (except for local radiation therapy, bisphos­
phonates, and cortico steroids), grade 2 or higher 
peripheral neuropathy, acute renal failure (unresponsive 
to up to 72 h of rehydration, characterised by creatinine 
>500 μmol/L or urine output <400 mL per day or 
requiring dialysis), active or previous hepatitis C 
infection, or women who were pregnant or lactating. 
Patients were identified and recruited through local 
multidisciplinary team meetings.
All patients provided written informed consent. The 
studies were approved by the national ethics review 
board (National Research Ethics Service, UK), 
institutional review boards of the participating centres, 
and the competent regulatory authority (Medicines and 
Healthcare Products Regulatory Agency, UK), and done 
according to the Declaration of Helsinki and the 
principles of Good Clinical Practice as espoused in the 
Medicines for Human Use (Clinical Trials) Regulations.
In both trials, patients who were young and fit 
enough to tolerate autologous stem­cell transplantation 
(transplant­eligible) entered the intensive treatment 
pathway; these patients are not considered in this 
analysis. Older and less fit patients (transplant­ineligible) 
entered the non­intensive treatment pathway. Strict age 
limits were deliberately avoided so that fit, older patients 
could receive intensive therapy and autologous stem­cell 
transplantation. The decision of treatment pathway was 
made on an individual patient basis, taking into account 
performance status, clinician judgement, and patient 
preference.
Patients, clinicians, and the trial team were aware of 
the randomised allocation as the study was open­label. At 
the time of this analysis, the trial results of NCRI­XI were 
not published and so no analysis stratified by randomised 
allocation is reported here. The primary and secondary 
outcomes of the MRC­IX study have been published 
previously.14–19
Procedures
In the NCRI­XI study, transplant­ineligible patients 
were randomly assigned to receive attenuated­dose 
versions of the oral cyclophosphamide, thalidomide, 
and dexamethasone regimen (CTDa; cyclophosphamide 
500 mg weekly, thalidomide initially 50 mg daily for 
28 days and increasing every 28 days by 50 mg increments 
to 200 mg daily, and dexamethasone 20 mg daily 
on days 1–4 and 15–18) or the oral cyclophosphamide, 
lenalidomide, and dexamethasone induction regimen 
(CRDa; cyclophosphamide 500 mg on days 1 and 8, 
lenalidomide 25 mg daily for 21 days, and dexamethasone 
20 mg daily on days 1–4 and 15–18). Treatment continued 
for at least six cycles in the absence of progressive 
disease, until maximum response or intolerance was 
observed. Patients randomly assigned to the immuno­
modulatory­based triplet regimens followed a response­
adapted approach. Those with complete response or very 
good partial response proceeded directly to maintenance 
randomisation. All patients with partial response or 
minimal response were randomly assigned to receive up 
to eight cycles of cyclophosphamide, bortezomib, and 
dexamethasone (CVD; cyclophos phamide 500 mg on 
days 1, 8 and 15, bortezomib 1·3 mg/m² subcutaneously 
or intravenously admin istered on days 1, 4, 8, and 11, and 
dexamethasone 20 mg daily on days 1–2, 4–5, 8–9, and 
11–12) or no additional treatment before maintenance 
randomisation. Patients with less than minimal response 
all received up to eight cycles of CVD. For maintenance 
therapy, at maximum response for transplant­ineligible 
patients, patients were initially allocated to receive either 
lenalidomide 25 mg per day (orally on days 1–21 of each 
28­day cycle) or observation. Following a protocol 
amendment on Sept 14, 2011, patients were allocated to 
receive lenalidomide 10 mg per day (orally on days 1–21 
of each 28­day cycle), lenalidomide plus vorinostat, or 
observation within protocol version 5.0. A further 
protocol amendment to version 6.0 was implemented on 
June 28, 2013, where patients were allocated to receive 
lenalidomide 10 mg per day (orally on days 1–21 of each 
28­day cycle) or observation, and the lenalidomide plus 
vorinostat group was discontinued because of withdrawal 
of the supply of vorinostat.
In the MRC­IX study, transplant­ineligible patients 
were randomly assigned to either oral melphalan and 
prednisone (7 mg/m² melphalan and 40 mg prednisone, 
both on days 1–4) or to attenuated­dose versions of the 
oral cyclophosphamide, thalidomide, and dexamethasone 
regimen (CTDa; cyclophosphamide 500 mg weekly, 
thalidomide initially 50 mg daily for 28 days and 
increasing every 28 days by 50 mg increments to 200 mg 
daily, and dexamethasone 20 mg daily on days 1–4 and 
15–18). Treatment continued for at least six cycles in the 
absence of progressive disease, until maximum response 
or intolerance was observed, up to a maximum of 
nine cycles. Patients were also assigned to bisphosphonate 
treatment (oral clodronic acid 1600 mg per day or 
intravenous zoledronic acid 4 mg every 21–28 days with 
induction chemotherapy, and every 28 days thereafter). 
After initial therapy, all eligible patients were randomly 
assigned to low­dose thalidomide maintenance therapy 
given until disease progression (50 mg daily for 28 days, 
increasing thereafter to 100 mg daily if well tolerated) or 
observation.
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In both trials, response and progression were assessed 
according to International Myeloma Working Group 
(IMWG) Uniform Response criteria18,19 and reviewed 
centrally by an expert panel, which was masked to 
treatment allocation.
For this study, as well as in the trials, patients were 
classified according to the presence of adverse risk 
cytogenetics, defined as gain(1q), t(4;14), t(14;16), t(14;20) 
and del(17p), as: genetic standard risk (no adverse 
lesions); genetic high risk (one adverse lesion); or genetic 
ultra­high risk (two or more adverse lesions)20 and also by 
use of the IMWG definition of adverse cytogenetic risk, 
defined as t(4;14), t(14;16) and del(17p), as: genetic 
standard risk (no adverse lesions) and genetic high risk 
(one or more adverse lesions).21,22
Outcomes
The primary endpoint used for the development and 
validation of the UK Myeloma Risk Alliance Risk Profile 
(MRP) was overall survival. Overall survival was defined 
as the time from randomisation to death from any cause. 
Otherwise, patients were censored at the time they were 
last known to be alive. Various exploratory endpoints 
were also analysed: progression­free survival, early 
mortality, percentage of protocol dose delivered 
(NCRI­XI only), and health­related quality of life 
(MRC­IX only). Progression­free survival was defined as 
the time from randomisation to the date of progression 
or death from any cause or censored at the time the 
patient was last known to be alive and progression free. 
Early mortality was defined as death within 60 days of 
randomisation (yes or no). Time­to­event endpoints for 
this analysis were censored at the date of database lock: 
Oct 28, 2016, in NCRI­XI and Jan 5, 2012, in MRC­IX. 
Data about the percentage of protocol dose delivered 
were available in NCRI­XI only and defined as the 
percentage delivered of the minimum protocol dose 
defined for induction treatment (six cycles of treatment) 
and the maximum protocol dose defined for 
consolidation treatment (eight cycles). Patient­reported 
health­related quality of life was available in MRC­IX 
only and was defined with the 20 subscales of the scored 
versions of the EORTC QLQ­C3023 and the EORTC 
QLQ­MY24 questionnaires.24,25
Statistical analysis
Patient characteristics and biochemical and haematological 
measurements, collected before treatment initiation, 
were considered potential prognostic variables. These 
were chosen as they were relatively easy to assess or were 
commonly available when patients presented. The 
potential prognostic variables included WHO performance 
status, lactate dehydrogenase (LDH), CRP, international 
staging system (ISS), age, and the ratio of lymphocytes to 
total white blood cells (L:W). WHO performance status 
(0–5) and ISS (I­III) were treated as ordinal variables and 
modelled with polynomial contrasts. LDH, CRP, age, and 
L:W were treated as continuous variables, where LDH was 
transformed with log transformations and CRP with 
(log+1) transformations. Complete case data in the 
training set (data from NCRI­XI) were defined as 
individuals having all potential prognostic variables 
NCRI-XI: training 
set
MRC-IX: test set
Included (n=1852) Included (n=520) Excluded (n=329) Total (n=849)
Median age 74·0 (71·0–78·0) 73·0 (70·0–77·0) 74·0 (70·0–77·0) 73·0 (70·0–77·0)
Age group (years)
<70 313 (17%) 129 (25%) 81 (25%) 210 (25%)
70–74 620 (34%) 189 (36%) 108 (33%) 297 (35%)
75–79 597 (32%) 131 (25%) 103 (31%) 234 (28%)
≥80 322 (17%) 71 (14%) 37 (11%) 108 (13%)
Sex
Men 1047 (57%) 285 (55%) 188 (57%) 473 (56%)
Women 805 (43%) 235 (45%) 141 (43%) 376 (44%)
WHO performance status
0 478 (26%) 93 (18%) 63 (19%) 156 (18%)
1 810 (44%) 238 (46%) 171 (52%) 409 (48%)
2 342 (18%) 111 (21%) 62 (19%) 173 (20%)
3 110 (6%) 68 (13%) 28 (9%) 96 (11%)
4 11 (1%) 10 (2%) 1 (0%) 11 (1%)
Data missing 101 (6%) 0 (0%) 4 (1%) 4 (1%)
ISS stage
I 318 (17%) 68 (13%) 42 (13%) 110 (13%)
II 731 (39%) 215 (41%) 97 (29%) 312 (37%)
III 659 (36%) 237 (46%) 96 (29%) 333 (39%)
Data missing 144 (8%) 0 (0%) 94 (29%) 94 (11%)
CRP (mg/L) 5·0 (3·0–16·0) 8·0 (4·0–20·0) 7·0 (5·0–19·0) 8·0 (4·0–20·0)
Data missing 262 0 276 276
LDH (IU/L) 278·0 
(190·0–396·5)
328·0 
(244·0–423·0)
324·0 
(230·0–433·0)
328·0 
(242·5–424·0)
Data missing 416 159 218 377
L:W 0·3 (0·2–0·4) 0·3 (0·2–0·3) 0·3 (0·2–0·4) 0·3 (0·2–0·4)
Data missing 7 2 2 4
Cytogenetic risk groups
Standard 399 (22%) 169 (33%) 84 (26%) 253 (30%)
High risk 265 (14%) 77 (15%) 52 (16%) 129 (15%)
Ultra-high risk 67 (4%) 43 (8%) 14 (4%) 57 (7%)
NA 1121 (61%) 231 (44%) 179 (54%) 410 (48%)
Induction regimen
CTDa 924 (50%) 248 (48%) 178 (54%) 426 (50%)
CRDa 928 (50%) NA NA NA
MP NA 272 (52%) 151 (46%) 423 (50%)
Allocated bisphosphonate
Sodium 
clodronate
NA 267 (51%) 156 (47%) 423 (50%)
Zoledronic acid NA 253 (49%) 173 (53%) 426 (50%)
CVD received
Yes 157 (8%) NA NA NA
No 1695 (92%) NA NA NA
(Table 1 continues on next page)
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recorded. Missing data were imputed via multiple 
imputation by chained equations to create ten imputed 
datasets.26
Continuous variables were standardised with the mean 
and SD within each imputed dataset. Preliminary 
investigations consisted of univariate Cox proportional 
hazards models, considering the association between 
overall survival and each individual potential prognostic 
variable, within each imputed dataset. Coefficients and 
standard errors were combined with Rubin’s rules.27 A 
multivariable penalised Cox model was estimated to 
investigate the association between the potential 
prognostic variables and overall survival within each 
imputed dataset to give ten models.28 A least absolute 
shrinkage and selection operator penalty term was 
applied and the same penalty parameter was used within 
each imputed dataset. The penalty term was estimated as 
the average of the optimal values, estimated separately by 
cross­validation, within each imputed dataset. Standard 
errors for the coefficients from each model were obtained 
via bootstrap methods.29
The calibration of the ten models was assessed with 
predicted versus observed probability plots and the 
discrimination of the models was assessed with the 
prog nostic separation D­statistic (D­statistic). For 
calibration, predicted versus observed probability plots 
were plotted at 60 days and 1 year after randomisation. 
The nature of censoring within survival data resulted in 
the predicted probability being calculated with the 
interval approach, similar to that described by Harrell 
and colleagues.30 To account for the full range of 
probabilities appropriately, ten intervals were chosen, 
similar to the calibration assessment done by Clark and 
Altman.26 The observed probabilities were calculated via 
the Kaplan­Meier method. The D­statistic is a measure 
of discrimination for time­to­event endpoints, of which 
higher values indicate better discrimin ation.31 The 
measure is essentially a log­hazard ratio from a Cox 
model—it can take any value on the real line and a value 
of zero is comparable to a hazard ratio of one in which 
there is no difference in two survival curves, or a value 
of approximately –0·693 is comparable to a hazard ratio 
of 0·5 and a value of approximately 0·693 is comparable 
to a hazard ratio of 2. The D­statistic has been 
successfully applied in the development and validation 
of various risk models32–34 and is acknowledged within 
the TRIPOD (transparent reporting of a multivariable 
prediction model for individual prognosis or diagnosis) 
reporting guidelines as an appropriate measure of 
discrimination.35 
The MRP was obtained by combining the estimates from 
the ten models using Rubin’s rules. It was assessed by 
summarising the calibration results across the ten imputed 
datasets with the median and IQR and combining the 
discrimination results by use of Rubin’s rules.36 This 
combination of the discrimination results gave the 
combined D­statistic.
The MRP was internally validated with the D­statistic 
within a bootstrap validation process,30 while accounting 
for imputation.37 A validation rule was prespecified as 
follows: if the corrected D­statistic lay within the 95% CI 
for the combined D­statistic then the MRP was concluded 
to be internally validated. The MRP was retrospectively 
externally validated with relevant complete case data 
from the test dataset (data from MRC­IX), where an 
individual was defined to have relevant complete case 
data if they had all the variables included in the MRP 
recorded. Variables in MRC­IX were standardised 
identically to NCRI­XI. External validation used the 
coefficients from the MRP to obtain the prognostic index 
(linear predictor), from which the D­statistic was 
estimated. An external validation rule was also 
prespecified: if the 95% CI for the D­statistic in MRC­IX 
overlapped with the 95% CI for the combined D­statistic 
in NCRI­XI then the MRP would be concluded to be 
externally validated.
The prognostic index of the MRP was obtained by 
combining the prognostic indices of the models 
estimated within the ten imputed datasets with Rubin’s 
rules. The tertiles of this combined prognostic index 
were used to trichotomise individuals into the MRP 
groups: low risk, medium risk, and high risk. The 
same bounds were applied in MRC­IX to obtain a 
similar division of patients. The distributions of the 
prognostic variables considered were compared across 
the MRP groups to assess their clinical appropriateness. 
The MRP groups were then used to stratify overall 
survival with Kaplan­Meier estimates of the survivor 
function. The discrimination of this model was 
assessed with the grouped version of the D­statistic. 
Exploratory and subgroups analyses are described in 
the appendix (p 2).
NCRI-XI: training 
set
MRC-IX: test set
Included (n=1852) Included (n=520) Excluded (n=329) Total (n=849)
(Continued from previous page)
Maintenance regimen
Observation 318 (17%) 93 (18%) 70 (21%) 163 (19%)
Thalidomide NA 97 (19%) 66 (20%) 163 (19%)
Lenalidomide 407 (22%) NA NA NA
Lenalidomide and 
vorinostat
111 (6%) NA NA NA
No maintenance 
regimen
1016 (55%) 330 (63%) 193 (59%) 523 (62%)
Data are n (%) or median (IQR). NCRI-XI=NCRI Myeloma XI. MRC-IX=MRC Myeloma IX. ISS=International Staging 
System. CRP=C-reactive protein. LDH=lactate dehydrogenase. L:W=lymphocyte to total white blood cell ratio. NA=not 
applicable. CTDa=attenuated cyclophosphamide, thalidomide, and dexamethasone. CRDa=attenuated 
cyclophosphamide, lenalidomide, and dexamethasone. MP=melphalan and prednisolone. CVD=cyclophosphamide, 
bortezomib, and dexamethasone. Standard risk was defined as the absence of any of the risk lesions: t(4;14), t(14;16), 
t(14;20), del(17p) and gain(1q). High risk was defined as one lesion present. Ultra-high risk was defined as more than 
one lesion present (UK definition). High risk and ultra-high risk categories were combined and defined as high risk 
for the analysis.
Table 1: Baseline characteristics and treatment details for the training and test datasets
See Online for appendix
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Statistical analyses were done in SAS, version 9.4, 
and R.
Role of the funding source
The funders had no role in study design, data analysis, data 
interpretation, or writing of the manuscript. All authors 
had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
The authors are solely responsible for study design, data 
collection, data analysis, data interpretation, writing of the 
report, and decisions about submission for publication. 
Results
The NCRI­XI study recruited 1852 previously untreated 
transplant­ineligible patients between May 25, 2010, and 
April 20, 2016, with a median age of 74 years (IQR 71–78). 
322 (17%) of 1852 trial participants were aged 80 years or 
older (table 1). All patients in the NCRI­XI study formed 
the training dataset, of whom 1268 (68%) had complete 
case data. The non­intensive pathway of the MRC­IX trial 
recruited 849 patients between May 14, 2003, and 
Nov 20, 2007, of whom 520 (61%) had complete case data 
and were included in the test dataset. Figure 1 shows the 
constituents of the test and training datasets from these 
trials, and the number of patients included in the various 
subgroups for exploratory analyses, with further details 
provided in the appendix (p 2). Patients in MRC­IX were 
slightly younger (933 [50%] of 1852 aged <75 years in 
NCRI­XI vs 318 [61%] of 520 in MRC­IX). Other baseline 
variables such as WHO performance status and ISS were 
similar (table 1). For the primary endpoint of overall 
survival, 700 (38%) of 1852 patients in NCRI­XI 
and 411 (79%) of 520 in MRC­IX had died at the time 
of analysis. For progression­free survival, 1273 (69%) 
Figure 1: Non-intensive pathways of the NCRI Myeloma XI and MRC Myeloma IX studies
Standard genetic risk defined as the absence of any of the risk lesions t(4;14), t(14;26), t(14;20), del(17p) and gain(1q); high genetic risk defined as the presence of at least one of these lesions. 
CRDa=attenuated cyclophosphamide, lenalidomide, and dexamethasone. CRP=C-reactive protein. CTDa=attenuated cyclophosphamide, thalidomide, and dexamethasone. CVD=cyclophosphamide, 
bortezomib, and dexamethasone. ISS=International Staging System. MP=melphalan and prednisolone. MRC-IX=MRC Myeloma IX. NCRI-XI=NCRI Myeloma XI. QoL=quality of life.
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of 1852 patients had an event in NCRI­XI, as did 
500 (96%) of 520 in MRC­IX. For early mortality, 83 (4%) 
of 1852 patients died within 60 days of randomisation in 
NCRI­XI, as did 36 (7%) of 520 in MRC­IX.
The univariate Cox model showed that age, L:W, CRP, 
and the linear element of WHO performance status and 
the linear element of ISS were significantly associated 
with overall survival (table 2). The MRP included the 
linear and quadratic terms of WHO performance status, 
the linear term of ISS, age, and CRP, demonstrating that 
WHO performance status, ISS, age, and CRP are 
associated with overall survival in a multivariable 
analysis (table 2). The calibration and discrimination of 
the MRP were good. Comparing calibration at 60 days 
after randomisation (appendix p 3) to calibration at 
1 year after randomisation (appendix p 3) showed that 
the model is better calibrated closer in time to baseline, 
as the intervals for each risk group intersect with the 
desired line representing perfect calibration for 60 days 
after randomisation compared with 1 year after 
randomisation. The combined D­statistic for the MRP 
was 0·840 (95% CI 0·718–0·963), demonstrating good 
discrimination of outcome. The corrected D­statistic 
from the internal validation process was 0·801 and 
the D­statistic for the MRC­IX model was 0·654 
(95% CI 0·497–0·811). The inclusion of the corrected 
D­statistic and the overlap between confidence intervals 
demonstrates that the MRP was successfully internally 
and retrospectively externally validated according to 
prespecified criteria.
The MRP scoring algorithm (appendix p 4) categorises 
individuals into groups: low, medium, and high risk, 
where the cutoff points represent the tertiles of the 
combined prognostic index (33%: –0·256; 66%: –0·0283). 
Each of the variables considered as prognostic factors 
increased in severity across the three groups, in both 
MRC­IX and NCRI­XI (appendix p 10). The MRP groups 
were associated with overall survival in both NCRI­XI 
(figure 2A) and MRC­IX (figure 2B).
The MRP groups were also associated with progression­
free survival in NCRI­XI (figure 2C) and MRC­IX 
(figure 2D).
The discrimination performance of the MRP groups 
for progression­free survival was acceptable because of 
the overlapping confidence intervals for the D­statistic 
(NCRI­XI D­statistic 0·455 [95% CI 0·355–0·554], 
MRC­IX D­statistic 0·360 [0·198–0·522]).
The MRP groups predicted early mortality in both 
studies. The area under the receiver operating char­
acteristic curve was 0·720 (95% CI 0·657–0·783) for the 
model within NCRI­XI and 0·660 (0·607–0·713) for the 
model within MRC­IX, demonstrating that the MRP 
groups had good discriminative ability. The odds ratio for 
early mortality compared with low­risk patients was 2·14 
(95% CI 1·04–4·42) for medium­risk patients and 4·76 
(2·44–9·27) for high­risk patients in NCRI­XI and 1·92 
(95% CI 0·35–10·54) for medium­risk patients and 10·59 
(2·48–45·17) for high­risk patients in MRC­IX 
(appendix p 10).
The percentage of protocol dose delivered in NCRI­XI 
was examined across the MRP groups to investigate the 
association between the risk profile and treatment 
tolerability. The median percentage of protocol dose 
delivered of induction therapy reduced as the risk to 
individuals increased (figure 3A). During induction, low­
risk patients received 88·57% (95% CI 67·53–100) of the 
minimum protocol dose, while medium­risk patients 
received 79·63% (53·98–97·22), and high­risk patients 
64·79% (23·28–88·69). This reduction is less marked in 
the CVD consolidation phase (figure 3B) where the 
Univariate model results Multivariable model results
Coefficient (SE) Hazard ratio (SE) 95% CI for HR Coefficient* (SE) Hazard ratio (SE) 95% CI for HR
WHO performance status
Linear 0·794 (0·269) 2·211 (1·309) (1·305–3·747) 0·629 (0·171) 1·875 (1·187) (1·340–2·624)
Quadratic –0·409 (0·231) 0·664 (1·260) (0·422–1·044) –0·001 (0·076) 0·999 (1·079) (0·861–1·160)
Cubic –0·098 (0·160) 0·907 (1·173) (0·663–1·240) 0 (0) 1 (1) 1 (1–1)
Quartic –0·027 (0·100) 0·973 (1·105) (0·800–1·184) 0 (0·001) 1 (1·001) (0·999–1·001)
Standardised age 0·260 (0·040) 1·296 (1·041) (1·198–1·402) 0·089 (0·040) 1·093 (1·041) (1·010–1·183)
ISS
Linear 0·617 (0·088) 1·853 (1·092) (1·560–2·201) 0·299 (0·075) 1·349 (1·078) (1·165–1·562)
Quadratic 0·080 (0·073) 1·084 (1·076) (0·940–1·250) 0 (0·015) 1 (1·015) (0·971–1·029)
Standardised L:W –0·180 (0·048) 0·835 (1·049) (0·760–0·917) 0 (0·007) 1 (1·007) (0·987–1·013)
Standardised 
transformed CRP
0·241 (0·038) 1·273 (1·038) (1·182–1·370) 0·035 (0·034) 1·036 (1·034) (0·970–1·106)
Standardised 
transformed LDH
0·054 (0·044) 1·055 (1·044) (0·969–1·149) 0 (0) 1 (1) (0·999–1·001)
CRP=C-reactive protein. HR=hazard ratio. ISS=International Staging System. L:W=lymphocyte to total white blood cell ratio. LDH=lactate dehydrogenase. NCRI-XI=NCRI 
Myeloma XI. *The coefficients marked as zero have been penalised during the model building process and are therefore not included in the UK Myeloma Research Alliance 
Risk Profile.
Table 2: Univariate Cox regression and multivariable penalised Cox regression model results for overall survival within the training dataset (NCRI-XI)
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percentage of protocol dose delivered was similar across 
all MRP groups, with no notable per­drug variability. 
This might have been due to the fact that only patients 
able to tolerate completion of initial induction therapy 
and judged to be able to tolerate the planned infusion 
therapy reached consolidation. The percentage of 
protocol dose delivered appears to be lower for 
consolidation than for induction overall, but this is due 
to the protocol stipulation of a minimum number of 
cycles for induction compared to a maximum number of 
cycles for consolidation.
Health­related patient reported quality­of­life subscales, 
measured at baseline, were compared across the MRP 
groups in MRC­IX. Of the 520 individuals in the test 
dataset, 466 (90%) had quality of life recorded at baseline. 
There was a clear association between worsening subscale 
scores and increase in risk, supporting stratification of 
patients with the MRP groups (figures 3C, D; 
appendix pp 5,6). For example, the median global health 
status/quality­of­life subscale from the EORTC QLQ­C30 
instrument decreased step­wise between low risk (66·7, 
IQR 50·0–83·3), medium risk (50·0, 33·3–66·7), and 
high risk (33·3, 16·7–50·0) groups. A similar association 
between worsening response and increase in risk was 
observed with the side­effects of treatment subscale from 
the EORTC QLQ­MY24 module.
Although derived in patients receiving the immuno­ 
modulatory agent containing regimens in NCRI­XI, the 
MRP groups remained prognostic for the 272 patients 
exposed to alkylator chemotherapy alone (melphalan plus 
prednisolone in MRC­IX) and in the 157 patients exposed 
to sequential immunomodulatory and proteasome 
inhibitor therapy (CVD consolidation in NCRI­XI; 
figure 4). The discriminatory power of the MRP groups 
was therefore not specific to the class of therapy used.
The MRP also remained prognostic within the 
cytogenetic risk groups (genetic standard and genetic 
high­risk) in both datasets according to the UK definition 
(NCRI­XI: n=731 [399 genetic standard risk, 332 genetic 
high­risk], figure 5; MRC­IX: n=289 [169 genetic standard 
risk, 120 genetic high­risk], appendix p 7) and according 
to the IMWG definition (MRC­IX: n=289 [231 genetic 
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Figure 2: Kaplan-Meier curves for overall survival and progression-free survival across the MRP groups
(A) Overall survival in the training population, NCRI Myeloma XI (NCRI-XI; n=1852). (B) Overall survival in the test population, MRC Myeloma IX (MRC-IX; n=520). 
(C) Progression-free survival in NCRI-XI (n=1852). (D) Progression-free survival in MRC-IX (n=520). MRP=UK Myeloma Research Alliance Risk Profile.
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Figure 3: Box-plots showing percentage of protocol dose delivered in NCRI-XI and EORTC QLQ-C30 subscale scores in MRC-IX across the MRP groups 
(A) Percentage of protocol dose delivered in NCRI Myeloma XI (NCRI-XI; n=1852) for induction regimen. (B) Percentage of protocol dose delivered in NCRI-XI (n=157) 
for consolidation regimen. (C) EORTC QLQ-C30 subscale scores in MRC Myeloma IX (MRC-IX; n=466) for global health status/quality of life. Higher values indicate 
improved response. (D) EORTC QLQ-C30 subscale scores in MRC-IX for side-effects of treatment measured at baseline. Higher values indicate worse response. All data 
are median (IQR). Symbols (round circles, +, and ×) indicate outliers. CRDa=attenuated cyclophosphamide, lenalidomide, and dexamethasone. CTDa= attenuated 
cyclophosphamide, thalidomide, and dexamethasone. CVD=cyclophosphamide, bortezomib, and dexamethasone. MRP=UK Myeloma Research Alliance Risk Profile. 
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Figure 4: Kaplan-Meier curves for overall survival by MRP groups in patients receiving combinations without immunomodulatory drugs
(A) CVD consolidation therapy in NCRI Myeloma XI (NCRI-XI; n=157). (B) Melphalan plus prednisolone in MRC Myeloma IX (MRC-IX; n=272). CVD=cyclophosphamide, 
bortezomib, and dexamethasone. MRP=UK Myeloma Research Alliance Risk Profile. NR=not reached.
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standard risk, 58 genetic high­risk]; NCRI­XI: n=731 
[598 genetic standard risk, 133 genetic high­risk] 
appendix pp 8,9). In all cases there was a similar 
discriminative performance to that observed overall, 
demonstrating the ability of the MRP group to determine 
outcome based on host biology, independently of tumour 
cell aggressiveness.
Discussion
Using data from two of the largest clinical trials done in 
newly diagnosed transplant­ineligible patients with 
multiple myeloma, we have derived a novel risk profile 
that appears to be prognostic of overall survival. The score 
uses prognostic factors regularly measured at baseline: 
laboratory blood tests (ISS and CRP), age, and a simple 
WHO performance status assessment, and therefore does 
not require any additional investigations or assessments 
in addition to standard of care. The risk profile has been 
successfully validated, internally and externally, according 
to predefined criteria. The risk profile is associated with 
progression­free survival, early mortality, and the 
percentage of protocol dose delivered. It is also associated 
with baseline quality­of­life subscales from commonly 
used patient­reported outcome measures. The risk profile 
also retains prognostic potential in patients treated with 
different mechanisms of action: alkylating agent regimens 
(eg, melphalan plus prednisolone), immunomodulatory 
triplets (eg, CTDa or CRDa) and in patients treated with a 
sequential combination of immunomodulatory agents 
and proteasome inhibitors (eg, CTDa or CRDa plus CVD). 
This indicates that this risk profile can be applied to 
patients treated with most therapeutic agents currently 
available in routine clinical practice for transplant­
ineligible patients with myeloma. Importantly, the risk 
profile is independently prognostic in genetic high­risk 
patients according to both the UK definition and the 
IMWG definition (used in defining the revised ISS), 
suggesting that in older patients the outcome is driven by 
both tumour and host biology.
The reference model with which the risk profile should 
be compared is the validated IMWG Frailty Score.8,9 This 
score requires completion of three questionnaires: the 
ADL,5 IADL,6 and the CCI.7 Such instruments potentially 
incorporate a degree of subjectivity, and can be open to 
bias. Additionally, the IMWG score remains influenced by 
age cutoffs, with all patients older than 80 years classified 
as frail. However, a limitation of this report is that in the 
NCRI­XI and MRC­IX trials these questionnaires were 
not administered and therefore a direct comparison is not 
possible. However, the MRP will be prospectively validated 
and compared with the IMWG Frailty Score in the UK­
MRA Myeloma XIV study (FiTNEss), which will begin in 
June, 2019, incorporating treatment strategies with the 
modern proteasome inhibitor ixazomib and the immuno­
modulatory agent lenalidomide in newly diagnosed 
transplant­ineligible patients with myeloma. Until such 
prospective validation is completed, the risk profile should 
only be used for research purposes.
The risk profile does not include adverse risk cyto­
genetics as a prognostic variable, although these have 
been shown by various academic groups to be important 
predictors of outcome in patients with myeloma. The 
definition of adverse risk cytogenetics differs between 
countries. For example, the UK defines t(4;14), t(14;16), 
t(14;20), del(17p) and gain(1q) as high­risk lesions,20 
whereas the IMWG include only a subset of these,21,22 
and others have also proposed inclusion of a high­risk 
gene expression profile.38 We have shown that the risk 
Figure 5: Kaplan-Meier curves for overall survival for patients with genetic standard and high risk profiles across the MRP groups
(A) Patients in NCRI Myeloma XI (NCRI-XI) with standard cytogenetic profiles (n=399). B) Patients in NCRI-XI with high-risk cytogenetic profiles (n=332). Standard 
risk defined as the absence of any of the risk lesions; t(4;14), t(14;16), t(14;20), del(17p) and gain(1q); high risk defined as the presence of at least one risk lesion 
(UK definition). MRP=UK Myeloma Research Alliance Risk Profile. NR=not reached.
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profile remains prognostic in genetic high­risk patients 
according to either the UK or IMWG definition and 
that the effect of the risk profile is both independent 
and additive (figure 5; appendix pp 5,6). We believe 
that, although there is currently no consensus 
concerning genetic high­risk disease, including such 
terms in a risk profile for older patients would not be 
useful as it might limit future applicability in the UK 
and worldwide.
The risk profile was developed in patients from 
clinical trials, which could be considered a limitation for 
general isability since clinical trials have stringent 
eligibility criteria—patients enrolled in these trials are 
different from those in the general population. 
Consequently, all risk profiles developed from clinical 
trial data, including that described here, might not 
necessarily provide outcome predictions that are 
representative of the general population. However, we 
do not believe this to be the case in our analysis, as the 
NCRI­XI and MRC­IX trials had relatively few exclusion 
criteria, recruited approximately 1000 patients per year 
at peak recruitment from a variety of centres, repre­
senting more than 30% of newly diagnosed patients 
with myeloma in the UK, and recruited a substantial 
proportion of patients aged older than 80 years, making 
them representative of the general population. 
Additionally, to further mitigate this limitation the risk 
profile will be externally validated in the MMRF 
CoMMpass Study, which includes real­world patients 
from Canada, Italy, Spain, and the USA.
Some of the treatment delivered in the trials used to 
develop and validate the risk profile could be considered to 
be old standard of care (eg, the melphalan plus 
prednisolone regimen and CTDa regimen) and perhaps 
suboptimal treatment options that might have negatively 
affected the outcome of patients. These treatments, and 
even the first­generation immunomodulatory agent 
thalidomide, are prescribed in various European countries 
and throughout the world, as shown in a recent summary 
of standard practice.39 However, a large proportion of 
patients in NCRI­XI, in whom the risk profile was derived, 
were receiving lenalidomide­based induction or main­
tenance, or both, and some patients also received 
consolidation treatment with the proteasome inhibitor 
bortezomib. Lenalidomide­based induction is a current 
standard­of­care regimen worldwide for transplant­
ineligible patients following the results of the FIRST 
study.40 The score remained prognostic in each of these 
treatment subgroups (data not shown).
The overall calibration of the MRP declines temporally 
further from trial entry. This might be due to the use of 
variables recorded at baseline, which could change over 
time. For example, if they are disease driven, CRP and 
WHO performance status could improve as the patient 
responds to treatment. Alternatively, these prognostic 
factors could worsen over time if they are driven by age 
or general health, or both.
There are numerous prognostic factors in myeloma 
that can be considered to be related to tumour biology, 
tumour burden, or host factors. These have been 
combined into staging systems and prognostic models 
that differ in the variables they select as important, which 
could be related to the different biological subgroups they 
are being informal surrogates for. The mSMART risk 
stratification guidelines include tumour biology factors 
and ignore tumour burden or host­related factors, which 
are important in older patients.41 In previous studies, 
frailty and outcome have been associated with activities of 
daily living, comorbidities, and age; the association with 
comorbidities has been demonstrated widely. For 
example, a population­based study demonstrated that 
comorbidity is more common in patients with myeloma 
than in the general population and is greater in patients 
older than 65 years.42 Different generic and myeloma­
specific comorbidity measures have been central to the 
development of the Revised Myeloma Comorbidity Index 
(R­MCI),10 which combines frailty assessment with renal 
and lung function assessments, age, and Karnofsky 
performance status. The R­MCI is suggested as an 
alternative to the IMWG frailty score10 that should be 
evaluated by IMWG and European Myeloma Network 
experts prospectively. We consider the MRP to be a 
further valid, and potentially less burdensome, alternative 
that will be prospectively evaluated.
Other proposed prognostic models have added 
laboratory measurements such as the concentration of 
N­terminal fragment of the type­B natriuretic peptide to 
simple factors such as age and WHO performance status 
to seek simple alternatives to the IMWG.43 The inclusion 
of such a biomarker can reflect biological subgroups that 
might have cardiac and renal disease. 43 Although arguably 
less specific, CRP might give similar indications con­
cerning biological subgroups, which could be comple­
mentary to the clinical and demographic variables in the 
MRP. We propose that laboratory measurements such as 
these could provide prognostic potential as well as geriatric 
assessment and deserve further study. The use of a 
biomarker­driven score in this setting could provide an 
easier system for clinicians to use with reduced possibility 
of inter­observer variability.
The standard approach to therapy in transplant­
ineligible patients with myeloma, and within each of the 
studies used to develop the risk profile, is to administer 
chemotherapy at full dose with a possible dose reduction 
for steroids, followed by reactive dose adjustments in the 
event of toxicities. The association of MRP groups with 
the percentage of protocol dose delivered suggests that 
the MRP might be able to predict early treatment 
cessation, which could enable pre­emptive, up­front dose 
adjustment of patients, preventing toxicity and potentially 
enabling patients to stay on therapy for longer. This 
possibility will be explored further alongside prospective 
validation of the risk profile in the UK­MRA Myeloma 
XIV (FiTNEss) study.
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